The benefits of using probiotics as adjuvant treatment in Alzheimer's disease
DOI:
https://doi.org/10.11606/issn.1679-9836.v103i4e-218868Keywords:
Alzheimer Disease, Microbiota, ProbioticsAbstract
Introduction: Alzheimer's Disease (AD) is a progressive and chronic disorder, characterized by the destruction of cholinergic neurons, by the deposit of neurofibrillary tangles and the presence of beta-amyloid plaques, being one of the main causes of dementia in the world. With the increase in the global population, life expectancy has been increasing exponentially over the decades, and diseases such as AD, which refer to the older adults, have shown a high incidence. The current most widespread drug treatments have restricted and ineffective effects, highlighting the need for therapeutic alternatives capable of reducing the adverse effects of conventional pharmacological therapies. Methodology: This is an integrative literature review study, in which the search period was between 2017 and 2022, through the PubMed and BVS databases. Results: 10 articles were found that answered the guiding question “What are the benefits of treatment with probiotics in the population affected by Alzheimer's Disease? ’’, and these were characterized by: title, authorship, year, database, journal, objective and conclusion. Discussion: Probiotics are able to activate immune processes that are essential in removing amyloid aggregates and damaged cells, in addition to modulating intestinal microbiota dysbiosis and microbiota-gut-brain axis deficits. Conclusion: Probiotics can refine physiological functions, barriers, intestinal homeostasis, immune response and modify brain function, providing good results on psychiatric and neurological diseases such as Alzheimer's Disease.
Downloads
References
Correia A, Filipe J, Santos A, Graça P. Nutrição e doença de Alzheimer. Programa Nacional para a Promoção da Alimentação Saudável. 2015. https://repositorio-aberto.up.pt/bitstream/10216/82649/2/116241.pdf.
Long JM, Holtzman DM. Alzheimer disease: an update on pathobiology and treatment strategies. Cell. 2019;179(2):312-39. Doi: https://doi.org/10.1016/j.cell.2019.09.001.
Holtzman DM, Morris JC, Goate AM. Alzheimer’s disease: the challenge of the second century. Sci Translat Med. 2011;3(77):77sr1-77sr1. Doi: https://doi.org/10.1126/scitranslmed.3002369.
Yang SJ, Shin H, Lee SH, Lee S. Functional linear regression model with randomly censored data: Predicting conversion time to Alzheimer’s disease. Computational Statistics & Data Analysis. 2020;150:107009. Doi: https://doi.org/10.1016/j.csda.2020.107009.
Korolev IO. Alzheimer’s disease: a clinical and basic science review. Medic Student Res J. 2014;4(1):24-33, 2014.
Magalhães T, Jesus B; Santana L. Aspectos clínicos e sociais dos portadores da doença de alzheimer na cidade de Muritiba-Ba. Enciclop Biosf. 2020;17(33). Doi: https://doi.org/10.1126/10.18677/EnciBio_2020C9.
World Health Organization. Dementia: a public health priority. World Health Organization. 2012. https://www.who.int/publications/i/item/dementia-a-public-health-priority.
Associação Brasileira de Alzheimer. Demência. 2019. https://abraz.org.br/?s=demencia.
Thomazi R, Silveira LV, Boas PJ, Jacinto AF. Frequência de demência em idosos internados em enfermaria de Geriatria de um hospital público Brasileiro. Dementia Neuropsychol. 2018;35-39. Doi: https://doi.org/10.1590/1980-57642018dn12-010005.
Querfurth HW, Laferla FM. Mechanisms of disease. New Eng J Med. 2020; 362(4):329-44. Doi: https://doi.org/10.1056/NEJMra0909142.
Lane CA, Hardy J, Schott JM. Alzheimer's disease. Europ J Neurol. 2018;25(1):59-70. Doi: https://doi.org/10.1111/ene.13439.
Oboudiyat C, Glazer H, Seifan A, Greer C, Isaacson RS. Alzheimer's disease. Semin Neurol. 2013;33(4):313-29. Doi: https://doi.org/10.1055/s-0033-1359319.
Delanogare E, Flores D, Souza RM, Souza L, Moreira EL. Hipótese amiloide e o tratamento da doença de Alzheimer: revisão dos estudos clínicos realizados. VITTALLE - Rev Ciênc Saúde. 2019;31(1):84-106. http://repositorio.furg.br/handle/1/7873.
Nocetti CT, Ribeiro TG. Uso de canabinoides como adjuvante no tratamento da Doença de Alzheimer. Braz J Surg Clin Res. 2020;32(3):104-11. https://www.mastereditora.com.br/periodico/20201106_103301.pdf.
Wilkins T, Sequoia J. Probiotics for gastrointestinal conditions: a summary of the evidence. Am Family Physic. 2017;96(3):170-8. https://pubmed.ncbi.nlm.nih.gov/28762696/.
Sharifi-Rad J, Rayess YE, Rizk AA, Sadaka C, Zgheib R, Zam W, et al. Turmeric and its major compound curcumin on health: bioactive effects and safety profiles for food, pharmaceutical, biotechnological and medicinal applications. Front Pharmacol. 2020;11:01021. Doi: https://doi.org/10.3389/fphar.2020.01021.
Chen Y, Xu J, Chen Y. Regulation of neurotransmitters by the gut microbiota and effects on cognition in neurological disorders. Nutrients. 2021;13(6):2099. Doi: https://doi.org/10.3390/nu13062099.
Caputi V, Giron MC. Microbiome-gut-brain axis and toll-like receptors in Parkinson’s disease. Int J Mol Sci. 2018;19(6):1689. Doi: https://doi.org/10.3390/ijms19061689.
Giau VV, Wu SY, Jamerlan A, An SSA, Kim SY, Hulme J. Gut Microbiota and Their Neuroinflammatory Implications in Alzheimer's Disease. Nutrients. 2018;10(11):1765. Doi: https://doi.org/10.3390/nu10111765
Mayer EA, Tillisch K, Gupta A. Gut/brain axis and the microbiota. J Clin Invest. 2015;125(3):926-938. Doi: https://doi.org/10.1172/JCI76304.
Quigley EM. Microbiota-brain-gut axis and neurodegenerative diseases. Cur Neurol Neurosci Rep. 2017;17(12):1-9. Doi: https://doi.org/10.1007/s11910-017-0802-6.
Soares CB, Hoga LA, Peduzzi M, Sangaleti C, Yonekura T, Silva DR. Revisão integrativa: conceitos e métodos utilizados na enfermagem. Rev Esc Enferm USP. 2014;48:335-45. Doi: https://doi.org/10.1590/S0080-6234201400002000020.
Leblhuber F, Steiner K, Schuetz B, Fuchs D, Gostner JM. Probiotic Supplementation in Patients with Alzheimer's Dementia - An Explorative Intervention Study. Curr Alzheimer Res. 2018;15(12):1106-13. Doi: https://doi.org/10.2174/1389200219666180813144834.
Yang X, Yu D, Xue L, Li H, Du J. Probiotics modulate the microbiota-gut-brain axis and improve memory deficits in aged SAMP8 mice. Acta Pharm Sin B. 2020;10(3):475-87. Doi: https://doi.org/10.1016/j.apsb.2019.07.001.
Kim CS, Cha L, Sim M, Jung S, Chun WY, et al. Probiotic Supplementation Improves Cognitive Function and Mood with Changes in Gut Microbiota in Community-Dwelling Older Adults: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial. J Gerontol A Biol Sci Med Sci. 2021;76(1):32-40. Doi: https://doi.org/10.1093/gerona/glaa090.
Bonfili L, Cecarini V, Gogoi O, Berardi S, Scarpona S. Gut microbiota manipulation through probiotics oral administration restores glucose homeostasis in a mouse model of Alzheimer's disease. Neurobiol Aging. 2020;87:35-43. Doi: https://doi.org/10.1016/j.neurobiolaging.2019.11.004.
Kobayashi Y, Sugahara H, Shimada K, Mitsuyama E, Kuhara T, et al. Therapeutic potential of Bifidobacterium breve strain A1 for preventing cognitive impairment in Alzheimer’s disease. Scientif Rep. 2017;7(1):1-10. Doi: https://doi.org/10.1038/s41598-017-13368-2.
Bonfili L, Gong C, Lombardi F, Cifone MG, Eleuteri AM. Strategic Modification of Gut Microbiota through Oral Bacteriotherapy Influences Hypoxia Inducible Factor-1α: Therapeutic Implication in Alzheimer's Disease. Int J Mol Sci. 2021;23(1):357. Doi: https://doi.org/10.3390/ijms23010357.
Kim H, Kim S, Park SJ, Park G, Shin H. Administration of Bifidobacterium bifidum BGN4 and Bifidobacterium longum BORI Improves Cognitive and Memory Function in the Mouse Model of Alzheimer's Disease. Front Aging Neurosci. 2021;13:709091. Doi: https://doi.org/10.3389/fnagi.2021.709091.
El Sayed NS, Kandil EA, Ghoneum MH. Probiotics Fermentation Technology, a Novel Kefir Product, Ameliorates Cognitive Impairment in Streptozotocin-Induced Sporadic Alzheimer's Disease in Mice. Oxid Med Cell Longev. 2021;2021:5525306. Doi: https://doi.org/10.1155/2021/5525306.
Batista LL, Malta SM, Silva HC, Borges LD, Rocha LO. Kefir metabolites in a fly model for Alzheimer's disease. Sci Rep. 2021;11(1):11262. Doi: https://doi.org/10.1038/s41598-021-90749-8.
Webberley TS, Masetti G, Bevan RJ, Kerry-Smith J, Jack AA, Michael DR, et al. The Impact of Probiotic Supplementation on Cognitive, Pathological and Metabolic Markers in a Transgenic Mouse Model of Alzheimer's Disease. Front Neurosci. 2022;16:843105. Doi: https://doi.org/10.3389/fnins.2022.843105.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Felipe Augusto Santos Nunes, Marcelo Luiz Peixoto Sobral
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
